Ruscogenin Ameliorates Experimental Nonalcoholic Steatohepatitis via Suppressing Lipogenesis and Inflammatory Pathway

Figure 6

The hepatic mRNA levels of β-oxidation-related genes (a) and lipogenic genes (b) in HFD-fed hamsters receiving 8 weeks of treatment with ruscogenin (3.0 mg/kg/day; HFD-RUS). The mRNA expressions of the β-oxidation-related genes and lipogenic genes were measured by RT-PCR and normalized to an internal control (β-actin). Animals not receiving any treatment were given the same volume of vehicle used to dissolve ruscogenin. Similar results were obtained with an additional 4 replications. Data were expressed as the mean with SEM (𝑛=5 per group) in each column. ^b𝑃<0.01 compared to vehicle-treated RCD-fed hamsters (RCD-vehicle). ^c𝑃<0.05 and ^d𝑃<0.01 compared to the values of vehicle-treated HFD-fed hamsters (HFD-vehicle) in each group, respectively.

(a)

(b)